BIEL BUZZ #1 on the Breakout Board with twice as many reads as SpaceX!
Thank you Ken Mayer for getting Electome off the ground with your start-up expertise and for leaving the company in good hands!
The addition of Erik A. Nilsen, PhD is a highly positive development for Electrome. While Ken Mayer brought valuable executive experience, Dr. Nilsen’s profile represents a significant upgrade in technical expertise, regulatory navigation, and institutional funding—three areas that are critical for a micro-cap electroceutical company looking to scale.
Here is a breakdown of why this transition is a strong net-positive for the company:
1. Perfect Technological Alignment
Electrome relies entirely on Bioelectronics proprietary pulsed shortwave therapy (PSWT) and neuromodulation technology (ActiPatch and RecoveryRx). Dr. Nilsen is a physicist with advanced degrees in electrical engineering and mathematics, and has spent over 25 years building bioelectric recording and stimulation systems. His deep technical fluency means he can directly spearhead the R&D and platform strategy without a learning curve (with assistance from John Martinez).
2. Regulatory & Institutional Credibility
For a medical device company, FDA clearances and clinical validations are everything. Dr. Nilsen’s bio highlights a strong track record of leading work across:
DARPA (Defense Advanced Research Projects Agency)
NIH (National Institutes of Health)
NIST ATP (National Institute of Standards and Technology)
His existing relationships and credibility with these high-level federal agencies could open doors for non-dilutive government grants, research partnerships, and smoother FDA-clearance pathways for new indications.
3. Track Record of Successful Exits
Dr. Nilsen has contributed to three successful company exits. This demonstrates that he doesn't just understand the science; he understands how to build corporate value, position a company for acquisition, or execute a strategy that rewards shareholders.
4. Capital Formation Expertise
Capital constraint is a constant hurdle for commercial growth and large-scale marketing. Dr. Nilsen’s noted background in "disciplined execution and capital formation" suggests he has the network and experience to attract institutional investors or strategic corporate partners, which Electrome needs to expand its global distribution footprint.
Summary
Moving from a traditional executive to a highly specialized, deeply credentialed scientist-entrepreneur like Dr. Nilsen signals that Electrome is moving toward aggressive technological scaling, institutional backing, and rigorous commercial expansion.
Thank you Ken Mayer for getting Electome off the ground with your start-up expertise and for leaving the company in good hands!
The addition of Erik A. Nilsen, PhD is a highly positive development for Electrome. While Ken Mayer brought valuable executive experience, Dr. Nilsen’s profile represents a significant upgrade in technical expertise, regulatory navigation, and institutional funding—three areas that are critical for a micro-cap electroceutical company looking to scale.
Here is a breakdown of why this transition is a strong net-positive for the company:
1. Perfect Technological Alignment
Electrome relies entirely on Bioelectronics proprietary pulsed shortwave therapy (PSWT) and neuromodulation technology (ActiPatch and RecoveryRx). Dr. Nilsen is a physicist with advanced degrees in electrical engineering and mathematics, and has spent over 25 years building bioelectric recording and stimulation systems. His deep technical fluency means he can directly spearhead the R&D and platform strategy without a learning curve (with assistance from John Martinez).
2. Regulatory & Institutional Credibility
For a medical device company, FDA clearances and clinical validations are everything. Dr. Nilsen’s bio highlights a strong track record of leading work across:
DARPA (Defense Advanced Research Projects Agency)
NIH (National Institutes of Health)
NIST ATP (National Institute of Standards and Technology)
His existing relationships and credibility with these high-level federal agencies could open doors for non-dilutive government grants, research partnerships, and smoother FDA-clearance pathways for new indications.
3. Track Record of Successful Exits
Dr. Nilsen has contributed to three successful company exits. This demonstrates that he doesn't just understand the science; he understands how to build corporate value, position a company for acquisition, or execute a strategy that rewards shareholders.
4. Capital Formation Expertise
Capital constraint is a constant hurdle for commercial growth and large-scale marketing. Dr. Nilsen’s noted background in "disciplined execution and capital formation" suggests he has the network and experience to attract institutional investors or strategic corporate partners, which Electrome needs to expand its global distribution footprint.
Summary
Moving from a traditional executive to a highly specialized, deeply credentialed scientist-entrepreneur like Dr. Nilsen signals that Electrome is moving toward aggressive technological scaling, institutional backing, and rigorous commercial expansion.
2
